A Rule Written for Packages, With a Specific Consequence
In June, U.S. Customs and Border Protection published a rule with an anodyne name: Indefinite Suspension of the De Minimis Exemption for Mail Shipments and New Postal Informal Entry Process. The document rewrites the rules for goods arriving through the international postal network, and two of its provisions carry a compliance date: October 22, 2026. What happens on that date is the subject of warnings now reaching American households that buy prescription medication from Canadian pharmacies.
According to the Campaign for Personal Prescription Importation, an advocacy group that has been tracking the implementation, the planned enforcement by CBP and the Food and Drug Administration will prohibit pharmaceutical parcels sent by pharmacies outside the United States in almost all circumstances. Entry will be blocked, the group's advisory says, if the medication is commercially available in the United States, even when it costs significantly more, or if the supplying company specifically markets to Americans.
Canadian pharmacies have begun emailing customers, advising them to request refills before the deadline.
Who This Affects
The group estimates that more than 4 million Americans rely on personal importation to afford prescription drugs, a figure that has been cited in congressional testimony and that no government agency disputes publicly. The typical customer is a person with a chronic condition and an expensive brand-name prescription, often uninsured or underinsured, who discovered that the identical medication sells for a fraction of the American price across the border.
The pathway has existed for decades on a legal fiction. Importing prescription drugs for personal use is generally not permitted under the Federal Food, Drug, and Cosmetic Act, but the FDA chose not to enforce that prohibition against individuals in limited circumstances. Enforcement discretion, not law, created the Canadian pharmacy market, and the new enforcement posture replaces that discretion with a blanket prohibition. The rule's stated rationales are drug screening and tariff compliance. Its practical consequence is that the price differential between American and Canadian pharmacy shelves stops mattering, because the Canadian shelf is no longer reachable by mail.
The Case Each Side Makes
The government's argument is procedural and public. CBP has said personal prescription importation does not comply with FDA guidelines, and the executive orders underlying the postal rules frame the mail channel as a vector for illicit drugs. From the enforcement perspective, a rule that cannot distinguish an Eliquis parcel from a fentanyl parcel ends by blocking both.
The patient-side argument is about outcomes rather than procedure. The importation group warns that people will face a choice between American retail prices and going without medication, and patient advocates note that the FDA's own discretion existed precisely because American drug prices create the demand that the new enforcement will not extinguish.
There is a third position, heard from pharmacists' associations on both sides of the border, which is more ambivalent than either camp. Organized pharmacy has never loved the importation market, which routes business around American pharmacies and raises its own safety questions about supply chains, but it also warns that patients pushed off imported medication may abandon therapy rather than pay retail.
The fair summary is that the rule will certainly change how millions of people buy medicine, and that the change will be hardest on the people the old discretion was designed to accommodate.
The Legal Machinery Behind the Date
The rule is an amendment to CBP's postal regulations, published in the Federal Register on June 24 and effective July 24, with a compliance date of October 22 for the provisions that matter here. Its stated foundations are the executive orders of February 2025 declaring national emergencies to address illicit drugs across the northern and southern borders, the April 2025 order on reciprocal tariffs, and Proclamation 11020 of April 2026, which adjusted imports of pharmaceuticals and pharmaceutical ingredients into the United States.
The drug-parcel consequence was not the headline of the rule. The document suspends the $800 de minimis exemption for goods arriving through the international postal network, a change aimed at closing the channel that the government says has carried illicit drugs and tariff-free merchandise. Prescription parcels get caught in the same net, which is why the practical effect for patients is a ban on almost all personal prescription shipments from abroad rather than a policy written about pharmacies.
The FDA's role is the enforcement layer. The agency's import pages describe a discretionary policy that has long allowed personal importation in limited circumstances, typically a supply of no more than about 90 days for conditions that are not well treated domestically. That discretion was never a right, and the new enforcement posture simply stops exercising it, which is legally straightforward and practically enormous for the people who depended on it.
The Safety Debate That Has Always Surrounded This Market
The importation market has always carried a safety argument in both directions. Its defenders point to the licensed Canadian pharmacies that dominate it, regulated by provincial authorities, and to the absence of documented harm from their shipments over a quarter century. The importation group states that its preferred sources have a 100 percent safety record, a claim about its own selected pharmacies.
Its critics point to the structural risks: unlicensed sellers that have used the same channel, counterfeit product, and the impossibility of the FDA inspecting every parcel. The agency's longstanding position has been that it cannot guarantee the safety of drugs bought outside the regulated domestic supply chain, which is the same position it takes about most imported consumer goods that bypass American oversight.
The honest framing is that both statements have always been true at once. The licensed Canadian pharmacies are not the counterfeit problem, and the counterfeit problem is not solved by closing the licensed pharmacies. What the rule changes is which risk the government has decided to prioritize, with the price paid by the legitimate end of the market.
What Happens If Nothing Changes
The importation group is pressing Congress to intervene before October 22, and the trade-policy backdrop gives the campaign a strange coalition: patient advocates, some pharmacists' associations, and members of both parties who have criticized the tariffs on Canada have reasons to object to the enforcement shift, though no legislative fix has materialized.
If the date arrives without one, the practical consequences are predictable. American retail prices become the only legal option for most of the affected patients, some will qualify for manufacturer assistance programs they never needed to investigate, and some will go without medication or stretch supplies, the outcome the care standards for chronic disease exist to prevent. The advisory from the pharmacies to request refills before the deadline is the clearest picture of the next five weeks: people are stocking up against a closing door, and the country is about to see how many of them were standing behind it.
Primary sources
- Federal Register, CBP rule 2026-12669 for the rule, its effective dates and the October 22 compliance date.
- Campaign for Personal Prescription Importation for the implementation warnings, the blocked-entry terms and the 4 million user estimate.
- FDA personal importation policy for the discretionary policy that created the market.